布地奈德、阿奇霉素联合特布他林治疗小儿急性支气管炎的临床疗效研究

Clinical efficacy of budesonide, azithromycin combined with terbutaline in the treatment of acute bronchitis in children

目的 探讨布地奈德、阿奇霉素联合特布他林治疗小儿急性支气管炎的临床疗效。方法 60例小儿急性支气管炎患儿,按随机数字表法分为实验组与对照组,各30例。对照组采用阿奇霉素、特布他林治疗,实验组在对照组基础上采用布地奈德治疗。对比两组疗效、症状消失时间、住院时间、不良反应发生率及治疗前后肺功能[第1秒用力呼气容积(FEV1)、呼气峰值流速(PEF)]。结果 实验组总有效率96.67%高于对照组的73.33%,差异具有统计学意义(P<0.05)。实验组咳嗽消失时间(6.23±0.61)d、啰音消失时间(4.61±0.56)d、发热消失时间(2.49±0.21)d、住院时间(7.06±0.86)d均短于对照组的(8.14±0.75)、(9.32±0.92)、(3.22±0.34)、(9.03±0.88)d,差异具有统计学意义(P<0.05)。治疗后,实验组FEV1(2.25±0.54)L、PEF(3.36±0.65)L/s高于对照组的(1.93±0.58)L、(2.85±0.61)L/s,差异具有统计学意义(P<0.05)。实验组不良反应发生率为6.67%,与对照组的10.00%比较,差异无统计学意义(P>0.05)。结论 采用布地奈德、阿奇霉素联合特布他林治疗小儿急性支气管炎可提高疗效,改善临床症状和肺功能,且具有用药安全性,值得临床推广。

Objective To discuss the clinical efficacy of budesonide, azithromycin combined with terbutaline in the treatment of acute bronchitis in children. Methods A total of 60 children with acute bronchitis were randomly divided into experimental group and control group, with 30 cases in each group. The control group was treated with azithromycin and terbutaline, and the experimental group was treated with budesonide on the basis of the control group. Both groups were compared in terms of clinical efficacy, symptom disappearance time, hospital stay, incidence of adverse reactions and pulmonary function [forced expiratory volume in one second(FEV1), peak expiratory flow rate(PEF)] before and after treatment. Results The total effective rate 96.67% of the experimental group was higher than 73.33% of the control group, and the difference was statistically significant(P<0.05). In the experimental group, the cough disappearance time was(6.23±0.61) d, the rales disappearance time was(4.61±0.56) d, the fever disappearance time was(2.49±0.21) d, the hospitalization time was(7.06±0.86) d,which were shorter than(8.14±0.75),(9.32±0.92),(3.22±0.34), and(9.03±0.88) d in the control group, and the differences were all statistically significant(P<0.05). After treatment, the FEV1(2.25±0.54) L and PEF(3.36±0.65) L/s of the experimental group were higher than(1.93±0.58) L and(2.85±0.61) L/s of the control group, and the differences were all statistically significant(P<0.05). The incidence of adverse reactions in the experimental group was 6.67%, and the difference was not statistically significant compared with 10.00% in the control group(P>0.05). Conclusion The use of budesonide, azithromycin combined with terbutaline in the treatment of acute bronchitis in children can enhance the clinical efficacy, improve clinical symptoms and pulmonary function, and has drug safety, which is worthy of clinical promotion.